key: cord-0994754-7lrqjrz4
authors: Blitz, Matthew J.; Rochelson, Burton; Minkoff, Howard; Meirowitz, Natalie; Prasannan, Lakha; London, Viktoriya; Rafael, Timothy J.; Chakravarthy, Shruti; Bracero, Luis A.; Wasden, Shane W.; Pachtman Shetty, Sarah L.; Santandreu, Orlando; Chervenak, Frank A.; Schwartz, Benjamin M.; Nimaroff, Michael
title: Maternal Mortality Among Women with COVID-19 Admitted to the Intensive Care Unit
date: 2020-06-15
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2020.06.020
sha: 54c6b92139b5dd9cbda55615760c19aaa2190a31
doc_id: 994754
cord_uid: 7lrqjrz4

nan

There is limited data on critically ill pregnant women hospitalized with coronavirus 55 disease 2019 . Although maternal mortality has been reported, 1-3 the 56 frequency with which this devastating outcome occurs is unknown. The objective of this 57 study was to determine the rate of maternal death among pregnant and postpartum 58 women with COVID-19 admitted to intensive care units (ICU) in a large integrated 59 health system in the New York metropolitan area. We describe patient demographics, 60 baseline comorbidities, clinical presentation, hospital course, and maternal outcomes. 61

This case series evaluated all consecutively hospitalized pregnant and immediately 64 postpartum women with laboratory-confirmed COVID-19 who were admitted to the ICU 65 at ten hospitals within Northwell Health, the largest academic health system in New 66 York, and Maimonides Medical Center, an affiliate of Northwell Health in Brooklyn, New 67

York, from March 1 -May 6, 2020. Collectively, these hospitals perform approximately 68 40,000 deliveries per year, which represents about 1 in 6 births in New York State and 1 69 percent of all births in the United States. Respiratory specimens were collected by 70 nasopharyngeal swab. Symptomatic patients with a positive result on severe acute 71 respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) 72 assay were included. Admission to the ICU was at the discretion of the consulted critical 73 care attending physician at each site. Patients who had a critical care consultation but 74 were not directly managed by an intensivist were not included. Women who tested 75 positive for the virus but were admitted to the ICU for indications other than acute or 76 impending hypoxemic respiratory failure were excluded (e.g. postpartum hemorrhage). 77

The Northwell Health Institutional Review Board approved this case series as minimal-78 risk research using data collected for routine clinical practice and waived the 79 requirement for informed consent. Some women in this study were included in previous 80 publications characterizing COVID-19 hospitalizations within the Northwell Health 81 system, 4,5 and one maternal death was previously presented as a case report. Between March 1 and May 6, 2020, at the eleven included hospitals, there were 462 98 pregnant women who tested positive for SARS-CoV-2, and 70 (15%) were classified as 99 severe or critical COVID-19 per National Institutes of Health (NIH) criteria. Out of these 100 70 patients, a total of 13 (19%) were admitted to the ICU for acute or impending 101 hypoxemic respiratory failure ( Figure 1 ). Among this group, 2 (15%) died and 11 (85%) 102

were discharged from the hospital. 103 104 Women admitted to the ICU had a mean maternal age of 33.8±5.2 years and 69% were 105 multiparous. Hispanic women constituted the largest racial/ethnic group (38%). The 106 most common comorbidities were obesity (38%) and pulmonary conditions (23%) such 107 as asthma and obstructive sleep apnea (OSA). However, nearly half of the patients 108 (46%) had no baseline comorbidities. All pregnancies were singleton gestations. The 109 majority of patients were tachycardic, tachypneic and hypoxemic on initial evaluation but 110 few were febrile. Nearly all patients (92%) met NIH criteria for severe COVID-19 at 111 admission. Lymphopenia, elevated transaminases, and elevated inflammatory markers 112

were common laboratory findings. The mean gestational age at hospitalization for 113 COVID-19 was 33.3±5.3 weeks, and symptoms started 8±3 days before admission. 114

The median length of hospitalization and ICU stay were 13 and 8 days, respectively. 116

The duration of hospitalization before ICU admission and after ICU discharge were 2±2 117 and 3±3 days, respectively. Invasive mechanical ventilation was required in 8 (62%) 118 cases (at initiation, 6 were postpartum and 2 were pregnant), and the median duration 119 of therapy was 8 days. Among this group, 7 (88%) required vasopressors. One patient 120 was extubated but remained ventilator-dependent with a tracheostomy. All patients 121 admitted to the ICU received either prophylactic or therapeutic dose anticoagulation 7 (100%); there were no known cases of venous thromboembolism. Most patients 123 received hydroxychloroquine (85%) and antibiotics for community-acquired pneumonia 124 (92%); some were enrolled in clinical trials for the antiviral drug remdesivir (23%), 125 interleukin-6-receptor inhibitors (38%), or convalescent plasma therapy (15%). 126

Of the two patients who died, one had a long, protracted course in the ICU complicated 128 by fetal demise at a periviable gestational age; she developed multiple organ failure, 129 required renal replacement therapy, and after extensive counseling in the setting of a 130 poor maternal prognosis, the family opted for no obstetrical intervention. She had a pre-131 pregnancy body mass index (BMI) greater than 40 kg/m 2 and OSA. The second patient 132 who died had a rapid clinical deterioration postpartum, which was complicated by 133 severe respiratory distress, multiple organ failure, and cardiopulmonary arrest. 1 She had 134 a pre-pregnancy BMI less than 30 kg/m 2 and no baseline comorbidities. Prone 135 positioning to improve oxygenation during mechanical ventilation was used in the first 136 case but not the second because of her rapid clinical decline. These cases were 137 critically reviewed by a multidisciplinary team; it was determined that the standard of 138 care was met in both cases, and that the outcomes were a consequence of the disease 139 process. At present, that study represents the largest report of such patients but it is limited by 160 the fact that half of the critically ill patients (11/20) were still hospitalized at the 161 completion of data collection. In our study, approximately half of the women admitted to 162 the ICU had no baseline comorbidities making it difficult to identify those who are at 163 highest risk of respiratory failure and death. The patients were generally older, 164 multiparous and racial/ethnic minorities, which may reflect underlying disease 165 prevalence (a product of various factors, including household size and ability to social 166 distance) rather than intrinsic susceptibility to adverse outcomes. Larger studies are 167 needed to determine which laboratory and imaging findings are most predictive of 168 rapidly progressive respiratory failure in pregnancy. In our study, most patients were 169 delivered in the setting of worsening disease; it is not known how autotransfusion and 170 other physiologic and immunologic changes immediately after delivery affect maternal 171 outcomes. 172 173 Strengths of this study include consecutive patient enrollment over a well-defined time 174

interval, explicit inclusion and exclusion criteria, utilization of data from a single medical 175 record system, and evaluation of clinically relevant outcomes. In addition, no patients 176 remained hospitalized at study completion, allowing all in-hospital outcomes to be fully 177 evaluated, without omission, further reducing the risk of bias. This study also has 178 limitations. First, our sample size remains small due to the rarity of ICU admissions 179 among pregnant women with COVID-19. 5 During the study, ICU bed availability was 180 limited and patients requiring significant non-invasive respiratory support (e.g. oxygen 181 delivery via nasal cannula or face mask) were often managed on lower acuity units. 182

Second, laboratory testing and radiologic imaging were not uniform. Third, treatment 183 algorithms changed throughout the study period and were not identical for all patients. 184

Finally, the true prevalence of COVID-19 among pregnant women in these communities 185 is unknown; a SARS-CoV-2 testing strategy that only includes patients admitted the 186 hospital, predominantly for delivery, doesn't reflect this number. Universal testing for 187 SARS-CoV-2 was implemented in the middle of the study period on our obstetrical Data are n (%) and mean ± standard deviation unless otherwise specified.

A Postpartum Death Due to Coronavirus Disease

Maternal Death Due to 209 COVID-19 Disease

Mortality of a pregnant patient diagnosed 211 with COVID-19: A case report with clinical, radiological, and histopathological findings

Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the 215

Intensive Care Unit Admissions for 217

Pregnant and Non-Pregnant Women with COVID-19

Clinical course of severe and 220 critical COVID-19 in hospitalized pregnancies: a US cohort study

Data are n (%), mean ± standard deviation, and median (interquartile range). a One patient was extubated but remained ventilator-dependent with a tracheostomy b Results not available for one newborn. c Denominator is number of patients diagnosed with COVID-19 at less than 37 weeks